TD Cowen raises Avita Medical stock price target on growth outlook

TD Cowen raised its price target for Avita Medical (RCEL) to $22.00 from $20.00, citing 20-25% annual revenue growth and stable operating expenses through 2027. The stock trades at $17.35, near its 52-week high. Avita reported Q3 2026 earnings beating estimates, with revenue up 53% year-over-year.

Original reporting
Published Nov 12, 2026, 2:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 2:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RCEL
Bullish
high confidence
Mentioned
$RCEL
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RCELBullishMed
01

Why it matters

The analyst's upgrade and target increase provide a fresh catalyst that could attract new buying, especially given the company's high gross margin and upcoming cash‑flow generation timeline.

02

Market read

Micro‑cap biotech with a new analyst target may see short‑term price appreciation.

03

What to watch

Potential regulatory or reimbursement hurdles for RECELL could temper growth.

Relevance 6/10Novelty 6/10Timing: today

Background

Avita Medical (RCEL) reported Q3 2026 earnings that beat expectations, prompting TD Cowen to lift its price target.

Company-level read

Ticker impact

$RCELBullishHigh confidence
Context

TD Cowen raised its price target on Avita Medical to $22 from $20 and highlighted Q3 earnings beat and growth outlook.

Expected impact

likely upward pressure as investors price in the new $22 target.

Evidence & confidence

Target raise of 10% with fresh earnings beat provides a clear catalyst for buying interest.

Market effects

Positive outlook for regenerative medicine and wound‑care sector may lift peers.

Limited to US biotech investors; no broader regional effect.

Minor, confined to niche biotech space.

Counterpoint

Target raise may be premature if cash generation delays beyond 2027.

Key entities

  • TD Cowen

    Equity research firm that raised the price target.

  • Avita Medical Ltd.

    Biotech firm developing RECELL and Cohealyx products.

Related articles

$RCELMed

Avita Medical Q3 Earnings Call Highlights

Avita Medical (RCEL) reported Q3 revenue of $600,000 for PermeaDerm, stable from Q2. Gross margin rose to 84%, and net loss narrowed to $6.2M. The company secured $10M in credit and alleviated going-concern doubts. RECELL revenue and manufacturing efficiencies drove improvements.

$RCELMed

AVITA Medical Reports Third Quarter Results

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AVITA Medical Reports Third Quarter Results Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., November 5, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic a

$RCELMedAI 8/10

Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%

Avita Medical (NASDAQ:RCEL) reported Q2 net loss of $7.7M, nearly $3M better than Q1, with cash use down to $3.2M and cash of $11.1M at quarter end. The company raised its 2026 revenue outlook and said it is within Perceptive Advisors debt revenue covenants, including a $73M 2026 target. Q2 sales rose 18%.